IP Library › Granted Patent US 12,565,535
Granted Patent B2
US 12,565,535 · App. 17/820,440 · Granted Mar 3, 2026

Chimeric antigen receptors targeted to PSCA

Inventors: Saul J. Priceman (Valley Village, CA); Christine E. Brown (Duarte, CA); Stephen J. Forman (Duarte, CA)
Assignee: City of Hope
C07K16/3069A61K35/17A61K40/11A61K40/31A61K40/4274A61K48/00A61P1/18A61P19/08A61P35/00A61P35/04C07H21/00C07H21/04C07K14/7051C07K14/70514C07K14/70517C07K14/70521C12N5/00C12N5/06C12N5/0602C12N5/0634C12N5/0636C12N5/10C12N15/00C12N15/09C12N15/10C12N15/11C12N15/62C12N15/63C12N15/70C12N15/74C12N15/79C12N15/85A61K2239/31A61K2239/38C07H19/00C07H19/06C07H19/16C07K2317/24C07K2317/53C07K2317/622C07K2317/73C07K2317/76C07K2319/02C07K2319/03C07K2319/33C12N15/8509C12N2015/8518C12N2015/8572
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,565,535
App. No.
17/820,440
Granted
Mar 3, 2026
Kind
B2
Abstract

Chimeric transmembrane immunoreceptors (CAR) targeted to PSCA are described.

Claims (28)

1 . A nucleic acid molecule encoding a chimeric antigen receptor (CAR) selected from the group consisting of:

(a) a CAR comprising a Prostate Stem Cell Antigen (PSCA) scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 9, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21;

(b) a CAR comprising a PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 2, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21; or

(c) a CAR comprising a PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 10, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21.

2 . The nucleic acid molecule of claim 1 , wherein the CAR comprises: PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 9, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21.

3 . The nucleic acid molecule of claim 1 , wherein the CAR comprises: a PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 2, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21.

4 . The nucleic acid molecule of claim 1 , wherein the CAR comprises: a PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 10, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21.

5 . A population of human T cells comprising a nucleic acid encoding a CAR selected from the group consisting of:

(a) a CAR comprising a PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 9, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21;

(b) a CAR comprising a PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 2, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21; or

(c) a CAR comprising a PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 10, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21.

6 . The population of human T cells of claim 5 , wherein the CAR comprises: PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 9, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21.

7 . The population of human T cells of claim 5 , wherein the CAR comprises: a PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 2, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21.

8 . The population of human T cells of claim 5 , wherein the CAR comprises: a PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 10, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21.

9 . The population of human T cells of claim 5 , wherein the population of T cells comprises central memory T cells.

10 . A CAR selected from the group consisting of:

(a) a CAR comprising a PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 9, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21;

(b) a CAR comprising a PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 2, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21; or

(c) a CAR comprising a PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 10 a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21.

11 . The CAR of claim 10 , wherein the CAR comprises: PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 9, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21.

12 . The CAR of claim 10 , wherein the CAR comprises: a PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 2, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21.

13 . The CAR of claim 10 , wherein the CAR comprises: a PSCA scFV comprising the amino acid sequence of SEQ ID NO: 38, a spacer comprising the amino acid sequence of SEQ ID NO: 10, a CD4 transmembrane domain comprising the amino acid sequence of SEQ ID NO: 16, a 41-BB co-stimulatory domain comprising the amino acid sequence of SEQ ID NO: 24, and CD3ζ domain comprising the amino acid sequence of SEQ ID NO: 21.

14 . A method for treating a human patient having a cancer expressing PSCA, the method comprising administering to the patient the population of human T cells of claim 5 .

15 . The method of claim 14 , wherein the population of human T cells are allogeneic to the patient.

16 . The method of claim 15 , wherein the cancer is prostate cancer.

17 . The method of claim 15 , wherein the cancer is a bone metastasis of prostate cancer.

18 . The method of claim 15 , wherein the cancer is pancreatic cancer.

19 . The method of claim 15 , wherein the CAR comprises an amino acid sequence selected from SEQ ID NOs: 26, 28, 30, 32, 34, and 36.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2022
From: PRICEMAN, SAUL J.; BROWN, CHRISTINE E.; FORMAN, STEPHEN J.
To: CITY OF HOPE
Reel/Frame 060839/0375 →
Continuity (3)
Continuation 15766674
Provisional Application 62238062 · Oct 6, 2015
Related Publication 20230348617A1 · Nov 2, 2023
References Cited (66)
US 11466097B2 · Priceman et al. · 2022 [cited by applicant]
US 20140090309A1 · Dumm · 2014 [cited by examiner]
US 20140356398A1 · Riddell · 2014 [cited by examiner]
US 20150139943A1 · Campana et al. · 2015 [cited by applicant]
US 20200308300A1 · Priceman et al. · 2020 [cited by applicant]
RU 2381234 · 2010 [cited by applicant]
WO WO2005000898 · 2005 [cited by applicant]
WO WO2009032949 · 2009 [cited by applicant]
WO WO2012079000 · 2012 [cited by applicant]
WO WO2014031687 · 2014 [cited by applicant]
WO WO2014144622 · 2014 [cited by applicant]
WO WO2015066551 · 2015 [cited by applicant]
WO WO2015105522 · 2015 [cited by applicant]
WO WO2015123527 · 2015 [cited by applicant]
WO WO2015157399 · 2015 [cited by applicant]
WO WO2016138034A1 · 2016 [cited by examiner]
WO WO2017027325 · 2017 [cited by applicant]
Han et al., Journal of Urology, Mar. 1, 2004;171(3):1117-21. (Year: 2004). [cited by examiner]
Zhigang et al., World J Surg Oncol. May 10, 2004;2:13, pp. 1-7. (Year: 2004). [cited by examiner]
Martin et al., Oncology Reports 31: 262-272, 2014. (Year: 2014). [cited by examiner]
Abate-Daga et al., “Supplemental Information for: ‘A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer,’” Human Gene Therapy, D… [cited by applicant]
Leyton et al., “Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors,” Protein Engineering, Design & Selection, Mar. 2009, 22(3):209-216. [cited by applicant]
Abate-Daga et al., “A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer,” Hum Gene Ther., Dec. 2014, 25(12):1003-1012. [cited by applicant]
Abate-Daga et al., “Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies,” Oncoimmunology, Jun. 18, 2014, 3:e29194-1-e29194-3. [cited by applicant]
Ahmed et al., “HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors,” Clin Cancer Res, Jan. 15, 2010, 16(2):474-485. [cited by applicant]
Bedouelle et al., “Diversity and junction residues as hotspots of binding energy in an antibody neutralizing the dengue virus,” FEBS J., Jan. 2006, 273(1):34-46. [cited by applicant]
Brown et al., “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?,” J Immunol., May 1, 1996, 156(9):3285-3291. [cited by applicant]
Brown et al., “Stem-like tumor-initiating cells isolated from IL 13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells,” Clin Cancer Res., Apr. 15, 2012, 18(8):2199-209. [cited by applicant]
Brown et al., “Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells,” J Immunol., 2007, 179(5):3332-3341. [cited by applicant]
Cartellieri et al., “Chimeric antigen receptor-engineered T cells for immunotherapy of cancer,” J Biomed Biotechnol, May 5, 2010, 2010, 21(4):427-413. [cited by applicant]
Cartellieri et al., “A Novel Ex Vivo Isolation and Expansion Procedure for Chimeric Antigen Receptor Engrafted Human T Cells,” PLOS ONE, Apr. 2014, 9(4):e93745. [cited by applicant]
Chow et al., “T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma,” Mol Ther., 2013, 21(3):629-637. [cited by applicant]
Colman “Effects of amino acid sequence changes on antibody-antigen interactions,” Research in Immunology, Jan. 1994, 145:33-36. [cited by applicant]
Diamond et al., “Somatic mutation of the T15 heavy chain gives rise to an antibody with autoantibody specificity,” Proc Natl Acad Sci USA., 1984, 81:5841-5844. [cited by applicant]
Dotti et al., “Design and development of therapies using chimeric antigen receptor-expressing T cells,” Immunological Reviews, Jan. 2014, 257(1):107-126. [cited by applicant]
Edelman et al., “The covalent structure of an entire gammaG immunoglobulin molecule,” Proc Natl Acad Sci USA, May 1969, 63(1):78-85. [cited by applicant]
European Search Report in European Application No. 20170726.2, dated Oct. 5, 2020, 20 pages. [cited by applicant]
Feldmann et al., “Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells,” J Immunol., 2012, 189:3249-3259. [cited by applicant]
Grada et al., “TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy,” Molecular Therapy-Nucleic Acids, Jan. 1, 2013, 2:e105. [cited by applicant]
Hong et al., “Successful treatment of melanoma brain metastases with adoptive cell therapy,” Clin Cancer Res, 2010, 16(19):4892-4898. [cited by applicant]
Hillerdal et al., “Systemic Treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice,” BMC Cancer, Jan. 2014, 14:30. [cited by applicant]
Hudecek et al., “The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity,” Cancer Immunology Research, Feb. 2015, 3(2):125-135. [cited by applicant]
Jonnalagadda et al., “Chimeric Antigen Receptors with Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy,” Mol Ther,. Apr. 2015, 23(4):757-68. [cited by applicant]
Jonnalagadda et al., “Chimeric antigen receptors (CARs) incorporating mutations in the IgG4 Fc spacer region to eliminate Fc receptor recognition results in improved CAR T cell persistence and anti-tumor efficacy,” Jour… [cited by applicant]
Katari et al., “Engineered T cells for pancreatic cancer treatment,” HPB., Sep. 2011, 13(9):643-650. [cited by applicant]
Klingemann, “Are natural killer cells superior CAR drivers?” Oncoimmunology, Jan. 1, 2014, 3(1):e28147. [cited by applicant]
Kunkele et al., “Functional Tuning of CARs Reveals Signaling Threshold above which CD8+ Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD,” Cancer Immunology Research, Apr. 1, 2015, 3(4):368-379. [cited by applicant]
Lepin et al., “An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors,” Eur J Nucl Med Mol Imaging., 2010, 37:1529-1538. [cited by applicant]
Long et al., “4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors,” Nature Medicine, May 4, 2015, 21(6):581-590. [cited by applicant]
Ohno et al., “Antigen-binding specificities of antibodies are primarily determined by seven residues of VH,” Proc Natl Acad Sci USA., May 1985, 82:2945-2949. [cited by applicant]
Priceman et al., “Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer,” Oncoimmunology, 2018, 7(2):e1380764. [cited by applicant]
Porter et al., “Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia” New England Journal of Medicine, Aug. 25, 2011, 365(8):725-733. [cited by applicant]
Pule et al., “A Chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells,” Molecular Therapy: The Journal of the American Society of Gene Therapy, Nov. 2005,… [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc Nat Acad Sci USA Immunology., 1982, 79:1979-1983. [cited by applicant]
Sampson et al., “EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss,” Clin Cancer Res., Feb. 15, 2014, 20(4):972-94. [cited by applicant]
Shi et al., “Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects,” Molecular Cancer, Sep. 2014, 13:219. [cited by applicant]
Tang et al., “The Foxp3+ regulatory T cell: a jack of all trades, master of regulation,” Nat Immunol., 2008, 9(3):239-244. [cited by applicant]
Vajdos et al., “Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis,” J Mol Biol., Jul. 5, 2002, 320(2):415-428. [cited by applicant]
Yaghoubi, “Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma,” Nat Clin Pract Oncol, Jan. 2009, 6(1):53-58. [cited by applicant]
Zhong et al., “Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment P13kinase/AKT/Bcl-XL Activation and CD8+ T cell-mediated Tumor Eradication,” Mol Ther., 2010, 18(2):413-420. [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2016/055761, dated Apr. 10, 2018, 12 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2016/055761, dated Feb. 14, 2017, 20 pages. [cited by applicant]
Frigault et al. “Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells,” Cancer Immunol Res., 2015, 3(4):356-367. [cited by applicant]
Craft et al., “Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process,” Cancer Res., 1999, 59(19):5030-5036. [cited by applicant]
Wang et al., “Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice,” Blood, 2011, 117(6):1888-1898. [cited by applicant]
Cooper et al., “T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect,” Blood 2003, 101:1637-1644. [cited by applicant]